Yale School of Medicine | Strategic Alliance Partners

“One of the reasons I so enjoy this conference is the multidisciplinary nature,” says Peter A. Humphrey, MD, PhD.

“This first disclosure of data supports the ongoing phase 2 and 3 programs evaluating enfor-tumab vedotin alone or in combination with pembrolizumab in MIBC,” said Daniel P. Petrylak, MD.

"These findings underscore the importance of screening guidelines from the task force and the rapid responsiveness of clinicians and patients,” said Michael S. Leapman, MD.

A recent study sought to investigate the trends in sudden and significant private equity acquisitions among urology practices between 2011 and 2021.

There was limited clinical activity with the combination in patients with HRD-negative tumors.

The SAP program cultivates a community of advocacy groups, medical associations, and medical institutions to foster collaboration and an open exchange of information among trusted peers for the ultimate benefit of patients and their families.

Michael E. Hurwitz, MD, PhD, discusses how immune checkpoint inhibitors have transformed the first-line setting in advanced renal cell carcinoma.

The decline in total testosterone was observed even among men with normal body mass index.

Pembrolizumab has been granted a second tumor-agnostic FDA indication, this one for patients with solid tumors with a high tumor mutational burden.

Neither oral nor gel testosterones show significant effect on liver function test results.

Prostatic artery embolization offers a safe and durably effective treatment for urinary retention and gross hematuria in challenging non-index BPH patients, according to the results of a retrospective study published in Urology (Nov. 14, 2019 [Epub ahead of print]).

Patients with ureteral stents are rarely lost to follow-up, but the risk is increased when patients are stented in an emergent setting rather than as part of an elective procedure, Yale University urologists reported at the 2018 World Congress of Endourology in Paris.